

IPS Pharma

Carbon Footprint Executive Summary




This is a summary of the Carbon Inventory and subsequent Footprint Report produced on behalf of IPS Pharma by Auditel for the reporting period 01/01/2023 to 31/12/2023. The inventory work and reporting were carried out in line with the GHG Protocol Corporate Accounting and Reporting Standard. The report has also undergone a verification by Auditel in line with ISO 14064-3 to provide a level of limited assurance, the outcome of which can be seen in the verifier's opinion statement attached to the full report. The full report should be considered when reading the summary and can be obtained at: www.ips-pharma.com

LOCATION BASED EMISSIONS & INTENSITY METRICS MARKET BASED

Scopes	tCO ₂ e
Scope 1	35.01
Scope 2 - Location based	51.15
Scope 3	135.55



Scopes	tCO ₂ e
Scope 1	35.01
Scope 2 - Market based	36.85
Scope 3	135.55



9.43

tCO₂e Per 1M Turnover

4.18


tCO₂e Per Employee

0.10

tCO₂e Per Sq Metre

9.43

tCO₂e Per 1M Sales



Location based	Total GHG emissions (tCO ₂ e)	Market based
35.01	Scope 1 - Direct Emissions from operations	35.01
28.05	Buildings	28.05
6.96	Fleet	6.96
51.15	Scope 2 - Indirect emissions use of purchased electricity, steam, heating, and cooling	36.85
51.15	Electricity	36.85
-	Purchased Steam, Heat & Cooling	-
65.40	Scope 3 - Indirect emission in the value chain - Upstream	65.40
-	Purchased Goods & Services	-
-	Capital Goods	-
23.18	Fuel & Energy Related Activities	23.18
25.93	Upstream Transport & Distribution	25.93
0.71	Waste Generated from Operations	0.71
1.38	Business Travel	1.38
14.19	Employee Commuting & Homeworking	14.19
-	Upstream Leased Assets	-
70.15	Scope 3 - Indirect emission in the value chain - Downstream	70.15
70.15	Downstream Transport & Distribution	70.15
-	Processing of Sold Products	-
-	Use of Sold Products	-
-	End of Life Treatment of Sold Products	-
-	Downstream Leased Assets	-
-	Franchises	-
-	Investments	-
221.71	Total GHG emissions (tCO ₂ e)	207.41